To Cite:
Graham
S, Harrod
M, Iversen
J, Simone Hocking
J. Prevalence of Hepatitis C Among Australian Aboriginal and Torres Strait Islander people: A Systematic Review and Meta-Analysis,
Hepat Mon.
2016
; 16(7):e38640.
doi: 10.5812/hepatmon.38640.
1. Hepatitis c virus projections working group: Estimates and projections of the hepatitis c virus epidemic in Australia. 2006;
2.
MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev. 1996; 18(2): 137-48[PubMed]
3.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
4. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. 2015;
5.
The health of Australia's prisoners. 2012;
6. Fourth National Aboriginal and Torres Strait Islander Blood-borne Viruses and Sexually Transmissible Infections Strategy, 2014-2017. 2014;
7.
Cunningham J, Rumbold AR, Zhang X, Condon JR. Incidence, aetiology, and outcomes of cancer in Indigenous peoples in Australia. Lancet Oncol. 2008; 9(6): 585-95
8. Main findings, bloodborne viral and sexually transmitted infections in aboriginal and torres strait islander people: Surveillance and evaluation report. 2015;
9.
Iversen J, Maher L. Australian needle and syringe program survey. 2015;
10.
Iversen J, Wand H, Topp L, Kaldor J, Maher L. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health. 2013; 103(8): 1436-44[DOI][PubMed]
11.
Nguyen O. Needle syringe programs: A return on investment. 2010; 17
12.
Kwon JA,
Anderson J,
Kerr CC,
Thein HH,
Zhang L,
Iversen J,
et al.
Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS. 2012; 26(17): 2201-10[DOI][PubMed]
13.
Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust. 2012; 196(10): 629-32[PubMed]
14. Doctors prescribing new hepatitis C treatments from today. 2016;
15.
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339[DOI][PubMed]
17.
Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007; 36(3): 666-76[DOI][PubMed]
18.
Boston RC, Sumner AE. STATA: a statistical analysis system for examining biomedical data. Adv Exp Med Biol. 2003; 537: 353-69[PubMed]
19.
Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust. 1997; 166(3): 127-30[PubMed]
20.
Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Aust N Z J Public Health. 1999; 23(4): 377-84[PubMed]
21.
Roberts C, Crofts N. Hitting up in the top end: characteristics of needle exchange clients in Darwin. Aust N Z J Public Health. 2000; 24(1): 82-5[PubMed]
22.
Gilles M, Swingler E, Craven C, Larson A. Prison health and public health responses at a regional prison in Western Australia. Aust N Z J Public Health. 2008; 32(6): 549-53[DOI][PubMed]
23.
van der Poorten D, Kenny DT, George J. Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. Med J Aust. 2008; 188(10): 610-4[PubMed]
24.
Templeton DJ,
Tyson BA,
Meharg JP,
Habgood KE,
Bullen PM,
Malek S,
et al.
Aboriginal health worker screening for sexually transmissible infections and blood-borne viruses in a rural Australian juvenile correctional facility. Sex Health. 2010; 7(1): 44-8[DOI][PubMed]
25.
Ward J,
Topp L,
Iversen J,
Wand H,
Akre S,
Kaldor J,
et al.
Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs. Aust N Z J Public Health. 2011; 35(5): 421-6[DOI][PubMed]
26.
Davies J, Jabbar Z, Gagan F, Baird RW. Blood-borne viruses in the haemodialysis-dependent population attending Top End Northern Territory facilities 2000-2009. Nephrology (Carlton). 2012; 17(5): 501-7[DOI][PubMed]
27.
Paquette D, McEwan M, Bryant J. Risk practices among aboriginal people who inject drugs in New South Wales, Australia. AIDS Behav. 2013; 17(7): 2467-73[DOI][PubMed]
28.
Foy A, Tierney A. Internal medicine in the bush: a clinical audit of a rural and remote outreach programme. Intern Med J. 2014; 44(4): 369-74[PubMed]
29.
Luciani F,
Bretana NA,
Teutsch S,
Amin J,
Topp L,
Dore GJ,
et al.
A prospective study of hepatitis C incidence in Australian prisoners. Addiction. 2014; 109(10): 1695-706[DOI][PubMed]
30.
Parker C,
Tong SY,
Dempsey K,
Condon J,
Sharma SK,
Chen JW,
et al.
Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcome. Med J Aust. 2014; 201(8): 470-4[PubMed]
31.
Harrod ME, Dore GJ, Gregson S, Belfrage M, Delaney-Thiele D, Hammond B. A descriptive analysis of routine HCV testing data from four Aboriginal Community Controlled Health Services: testing, positivity, follow-up and context of testing. 2014;
32.
Saulo D, Harrod ME, Reekie J, Kaldor J, Butler T. Blood borne virus prevalence and risk behaviours in Indigenous and non-Indigenous prison entrants. 2014;
33.
Su JY, Broadfoot J. Sero-prevalence of hepatitis C virus antibody among prisoners in the Northern territory. 2013; 20
34.
Kinner SA, Jenkinson R, Gouillou M, Milloy MJ. High-risk drug-use practices among a large sample of Australian prisoners. Drug Alcohol Depend. 2012; 126(1-2): 156-60[DOI][PubMed]
35. Sexual health and bloodborne viruses. 2012;
36.
Reekie JM,
Levy MH,
Richards AH,
Wake CJ,
Siddall DA,
Beasley HM,
et al.
Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010. Med J Aust. 2014; 200(5): 277-80[PubMed]
37.
Butler T, Callander D, Simpson M. National prison entrants’ bloodborne virus and risk behaviour survey 2004, 2007, 2010 and 2013. 2015;
Readers' Comments